Patents by Inventor Stephen J. Farr

Stephen J. Farr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190083425
    Abstract: Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.
    Type: Application
    Filed: November 19, 2018
    Publication date: March 21, 2019
    Applicant: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Stephen J. FARR, BROOKS BOYD
  • Publication number: 20190083424
    Abstract: Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.
    Type: Application
    Filed: November 16, 2018
    Publication date: March 21, 2019
    Applicant: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Stephen J. FARR, BROOKS BOYD
  • Publication number: 20180055789
    Abstract: Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.
    Type: Application
    Filed: August 2, 2017
    Publication date: March 1, 2018
    Applicant: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Stephen J. FARR, BROOKS BOYD
  • Publication number: 20170174614
    Abstract: Metabolism-resistant fenfluramine analogs are provided. The subject fenfluramine analogs find use in the treatment of a variety of diseases. For example, methods of treating epilepsy by administering a fenfluramine analog to a subject in need thereof are provided. Also provided are methods of suppressing appetite in a subject in need thereof. Pharmaceutical compositions for use in practicing the subject methods are also provided.
    Type: Application
    Filed: December 20, 2016
    Publication date: June 22, 2017
    Applicant: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Stephen J. FARR, Brooks M. BOYD
  • Publication number: 20170056344
    Abstract: A method of treating and/or preventing symptoms of Lennox-Gastaut Syndrome (LGS) also known as Lennox Syndrome in a patient such as a patient previously diagnosed with Lennox Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Lennox Syndrome patients are treated at a preferred dose of less than about 2.0 to about 0.01 mg/kg/day.
    Type: Application
    Filed: August 24, 2016
    Publication date: March 2, 2017
    Applicant: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Stephen J. FARR, Bradley S. GALER
  • Publication number: 20160199579
    Abstract: Improved needle free injectors comprising of a energy sources, triggering mechanisms, impact members, and drug delivery pistons are disclosed. In one preferred embodiment, the triggering mechanism comprises a spool which seals an energy source comprised of compressed gas and a component for releasing the spool to release the pressurized gas and urge a ram forward to force a drug containing formulation through a drug delivery orifice.
    Type: Application
    Filed: January 9, 2012
    Publication date: July 14, 2016
    Applicant: ZOGENIX, INC.
    Inventors: Brooks Boyd, Stephen J. Farr, Jeffery A. Schuster, Andy Fry, Andy Pocock, Brennan Miles, Chris Hurlstone, Joe Daintrey
  • Publication number: 20160166766
    Abstract: A drug delivery monitoring system comprising a monitor is disclosed that utilizes sound to monitor the occurrence and properties of a drug delivery event. The monitor is affixed to the exterior of a drug delivery device or drug container, and thus does not require disassembly of the drug delivery device and cannot interfere with the operation of the drug delivery device. The monitoring system includes a display device such as a smart phone or tablet computer for analyzing data related to the drug delivery device usage and displaying information to a patient or caregiver before, during, and after a drug delivery event.
    Type: Application
    Filed: July 11, 2014
    Publication date: June 16, 2016
    Applicant: OSCILLARI LLC
    Inventors: Jeffrey A. SCHUSTER, Stephen J. FARR
  • Publication number: 20160151571
    Abstract: Systems and methods are described for treating un-met medical needs in migraine and related conditions such as cluster headache. Included are treatments that are both rapid onset and long acting, which include sustained release formulations, and combination products. Also included are treatments for multiple symptoms of migraine, especially headache and nausea and vomiting. Systems that are self contained, portable, prefilled, and simple to self administer at the onset of a migraine attack are disclosed, and preferably include a needle-free injector and a high viscosity formulation, to eliminate such issues as fear of self administration with needles, and needle stick and cross contamination.
    Type: Application
    Filed: February 4, 2016
    Publication date: June 2, 2016
    Applicant: ZOGENIX, INC.
    Inventors: Stephen J. FARR, John TURANIN, Roger HAWLEY, Jeffrey A. SCHUSTER
  • Publication number: 20160129182
    Abstract: A monitoring system comprising a monitor is disclosed that utilizes a vibration sensor to monitor the occurrence and properties of an event. The monitor does not require disassembly of the device to be monitored, or interfere with the operation of the device to be monitored, because the monitor is affixed to the exterior of a device to be monitored or a component thereof, or is integrated into the design of the device to be monitored. In a preferred embodiment, the device to be monitored is a drug delivery device, most preferably an inhaler or autoinjector. The monitoring system includes a display device such as a smartphone or tablet computer for analyzing data related to the device to be monitored usage and displaying information to a user, patient and/or caregiver before, during, and after a usage event. Preferred embodiment monitor the inhalation flow rate through an inhaler, and the dose delivered by an injector.
    Type: Application
    Filed: January 14, 2016
    Publication date: May 12, 2016
    Applicant: OSCILLARI LLC
    Inventors: Jeffrey A. SCHUSTER, Stephen J. FARR, Reuben HALE
  • Publication number: 20160051466
    Abstract: Systems and methods are described for treating un-met medical needs in migraine and related conditions such as cluster headache. Included are treatments that are both rapid onset and long acting, which include sustained release formulations, and combination products. Also included are treatments for multiple symptoms of migraine, especially headache and nausea and vomiting. Systems that are self contained, portable, prefilled, and simple to self administer at the onset of a migraine attack are disclosed, and preferably include a needle-free injector and a high viscosity formulation, to eliminate such issues as fear of self administration with needles, and needle stick and cross contamination.
    Type: Application
    Filed: November 3, 2015
    Publication date: February 25, 2016
    Inventors: Stephen J. FARR, John TURANIN, Roger HAWLEY, Jeffrey A. Schuster
  • Patent number: 9186461
    Abstract: Formulations are described that are viscous and will benefit from needle-free delivery at high driving pressures. Conventional delivery of these viscous formulations by hypodermic syringes is inconvenient as well as painful. Formulations include those which have a viscosity of about 5 cS or more at about 20° C. and which can have 0.5 ml or more administered by a needle-free injector in about 0.1 second ±0.02 seconds.
    Type: Grant
    Filed: July 31, 2012
    Date of Patent: November 17, 2015
    Assignee: ZOGENIX, INC.
    Inventors: Brooks M. Boyd, Sujata Mudumba, Stephen J. Farr
  • Patent number: 8876758
    Abstract: Formulations are described that are viscous and will benefit from needle-free delivery at high driving pressures. Conventional delivery of these viscous formulations by hypodermic syringes is inconvenient as well as painful. Formulations include those which have a viscosity of about 5 cS or more at about 20° C. and which can have 0.5 ml or more administered by a needle-free injector in about 0.1 second±0.02 seconds.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: November 4, 2014
    Assignee: Zogenix, Inc.
    Inventors: Brooks M. Boyd, Sujata Mudumba, Stephen J. Farr
  • Publication number: 20140148485
    Abstract: Systems and methods are described for treating un-met medical needs in migraine and related conditions such as cluster headache. Included are treatments that are both rapid onset and long acting, which include sustained release formulations, and combination products. Also included are treatments for multiple symptoms of migraine, especially headache and nausea and vomiting. Systems that are self contained, portable, prefilled, and simple to self administer at the onset of a migraine attack are disclosed, and preferably include a needle-free injector and a high viscosity formulation, to eliminate such issues as fear of self administration with needles, and needle stick and cross contamination.
    Type: Application
    Filed: January 31, 2014
    Publication date: May 29, 2014
    Inventors: STEPHEN J. FARR, JOHN TURANIN, ROGER HAWLEY, JEFFREY A. SCHUSTER
  • Publication number: 20130231311
    Abstract: Systems and methods are described for treating un-met medical needs in migraine and related conditions such as cluster headache. Included are treatments that are both rapid onset and long acting, which include sustained release formulations, and combination products. Also included are treatments for multiple symptoms of migraine, especially headache and nausea and vomiting. Systems that are self contained, portable, prefilled, and simple to self administer at the onset of a migraine attack are disclosed, and preferably include a needle-free injector and a high viscosity formulation, to eliminate such issues as fear of self administration with needles, and needle stick and cross contamination.
    Type: Application
    Filed: April 16, 2013
    Publication date: September 5, 2013
    Inventors: Stephen J. FARR, John TURANIN, Roger HAWLEY, Jeffrey A. SCHUSTER
  • Publication number: 20120296270
    Abstract: Formulations are described that are viscous and will benefit from needle-free delivery at high driving pressures. Conventional delivery of these viscous formulations by hypodermic syringes is inconvenient as well as painful. Formulations include those which have a viscosity of about 5 cS or more at about 20° C. and which can have 0.5 ml or more administered by a needle-free injector in about 0.1 second±0.02 seconds.
    Type: Application
    Filed: July 31, 2012
    Publication date: November 22, 2012
    Inventors: Brooks M. Boyd, Sujata Mudumba, Stephen J. Farr
  • Patent number: 8066661
    Abstract: Formulations are described that are viscous and will benefit from needle-free delivery at high driving pressures. Conventional delivery of these viscous formulations by hypodermic syringes is inconvenient as well as painful. Formulations include those which have a viscosity of about 5 cS or more at about 20° C. and which can have 0.5 ml or more administered by a needle-free injector in about 0.1 second±0.02 seconds.
    Type: Grant
    Filed: February 15, 2008
    Date of Patent: November 29, 2011
    Assignee: Zogenix, Inc.
    Inventors: Brooks M. Boyd, Sujata Mudumba, Stephen J. Farr
  • Publication number: 20110196336
    Abstract: Formulations are described that are viscous and will benefit from needle-free delivery at high driving pressures. Conventional delivery of these viscous formulations by hypodermic syringes is inconvenient as well as painful. Formulations include those which have a viscosity of about 5 cS or more at about 20° C. and which can have 0.5 ml or more administered by a needle-free injector in about 0.1 second±0.02 seconds.
    Type: Application
    Filed: April 19, 2011
    Publication date: August 11, 2011
    Inventors: Brooks M. BOYD, Sujata Mudumba, Stephen J. Farr
  • Publication number: 20110118189
    Abstract: Systems and methods are described for treating un-met medical needs in migraine and related conditions such as cluster headache. Included are treatments that are both rapid onset and long acting, which include sustained release formulations, and combination products. Also included are treatments for multiple symptoms of migraine, especially headache and nausea and vomiting. Systems that are self contained, portable, prefilled, and simple to self administer at the onset of a migraine attack are disclosed, and preferably include a needle-free injector and a high viscosity formulation, to eliminate such issues as fear of self administration with needles, and needle stick and cross contamination.
    Type: Application
    Filed: April 24, 2009
    Publication date: May 19, 2011
    Inventors: Stephen J. Farr, John Turanin, Roger Hawley, Jeffrey A. Schuster
  • Publication number: 20090241950
    Abstract: The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patient=s breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation.
    Type: Application
    Filed: May 12, 2009
    Publication date: October 1, 2009
    Inventors: Igor Gonda, Reid M. Rubasamen, Stephen J. Farr
  • Patent number: 7490603
    Abstract: The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patient's breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation.
    Type: Grant
    Filed: November 21, 2005
    Date of Patent: February 17, 2009
    Assignee: Aradigm Corporation
    Inventors: Igor Gonda, Reid M. Rubsamen, Stephen J. Farr